In the Journals

HCV clearance reduces diabetes, kidney disease, stroke risk

August 23, 2019
Sustained virologic response after treatment for hepatitis C correlated with a reduced risk for several extrahepatic manifestations including type 2…

In the Journals

Military combat service linked to an increase in HBV exposure

August 21, 2019
The prevalence of exposure to hepatitis B among veterans was highest among those with traditional risk factors and independently related to military…

In the Journals

Patient-reported outcomes greatly altered by HCV treatment results

August 20, 2019
In a follow-up analysis of participants in clinical trials, researchers found that patient-reported outcome scores increased in patients who achieved…

In the Journals

Africans with HCV more likely to carry ‘unusual’ genotypes, face lower SVR

August 12, 2019
Most patients with hepatitis C in Africa have genotypes outside of the common and easily cured genotype 1a and genotype 1b, which has led to a…

In the Journals

Vosevi safely treats HCV in patients with prior treatment failure

August 1, 2019
Treatment with Vosevi, a combination of sofosbuvir, velpatasvir and voxilaprevir, was an effective and safe therapy for patients with prior…

In the Journals

‘Double negative’ HBV levels at end of treatment mark lower relapse risk

July 29, 2019
Patients who demonstrated negative results from tests for both hepatitis B DNA and RNA at the cessation of nucleos(t)ide treatment were less likely…

World Hepatitis Day: Recent steps toward reaching all patients

July 28, 2019
This year for World Hepatitis Day, the theme is “Find the Missing Millions.” Hundreds of millions of people living with viral hepatitis…

In the Journals

Decentralized telemedicine achieves high HCV cure rates in rural India

July 26, 2019
Decentralized treatment of hepatitis C using telemedicine clinics achieved a sustained virologic response rate of more than 90% regardless of…

In the Journals

USPSTF: Screen pregnant women for hepatitis B

July 23, 2019
The U.S. Preventive Services Task Force recently gave an ‘A’ level recommendation to screening women for hepatitis B in their first…

NAFLD, NASH leading 'economic tsunami' of liver disease in US

July 22, 2019
Stephen A. Harrison, MD, FACP, FAASLD, visiting professor of hepatology at University of Oxford and medical director at Pinnacle Clinical Research…

In the Journals

Concurrent NASH drives a ‘second hit’ to the liver in patients with HBV

July 19, 2019
Recent study data showed that concomitant chronic hepatitis B and nonalcoholic steatohepatitis were significantly more likely to lead to advanced…

Feature

AASLD Foundation presents grants to young hepatologists for research, careers

July 18, 2019
The American Association for the Study of Liver Diseases Foundation has granted $3.42 million in research and career development awards to 29…

In the Journals

Harvoni joins growing DAA options for younger patients with HCV

July 17, 2019
Harvoni joins other direct-acting antivirals in demonstrating safety and high efficacy in younger pediatric patients with chronic hepatitis C…

Feature

Telemedicine takes focus in study of HCV treatment in methadone centers

July 17, 2019
With $7 million from the Patient-Centered Outcomes Research Institute, seven opioid treatment programs announced entry into an ongoing study of…

HCV micro-elimination program seeks to cure high-risk Kentucky county

July 11, 2019
Intent Solutions announced a partnership with the University of Kentucky in a $15 million federal grant program aimed at eliminating hepatitis C in…

In the Journals

VCTE superior marker for measuring fibrosis in patients with HBV/HIV

July 10, 2019
Vibration-controlled transient elastography outperformed aspartate aminotransferase to platelet ratio index and Fibrosis-4 index as a noninvasive…

In the Journals

Mavyret cures 100% of adolescents with HCV in first of two-part pediatric study

July 9, 2019
The pangenotypic direct-acting antiviral Mavyret demonstrated 100% sustained virologic response in adolescent patients aged 12 years to 17 years with…

Enanta launches phase 1a study of HBV core inhibitor compound

July 8, 2019
Enanta Pharmaceuticals launched the first part of a phase 1a/b clinical study of EDP-514 for the treatment of hepatitis B, according to a press…

In the JournalsPerspective

HBV serostatus identification is critical before hemodialysis

July 3, 2019
A multistep process hemodialysis patients according to findings published in Infection Control Hospital Epidemiology. Dedicated equipment and a…

In the Journals

Veterans with PTSD at higher risk for death by suicide, accident, hepatitis

June 28, 2019
Compared with the general U.S. population, veterans with PTSD appeared at higher risk for death by suicide, accidental injury and viral hepatitis…

Healio Jobs